MKSI Shorts Rebuild as the Stock Loses Ground on Its Peers

The Street remains broadly constructive, though cracks have appeared. Most analysts raised targets following the Q2 report in early August, with Citigroup lifting to $430, JPMorgan to $380, and Needham to $390. Mizuho was the outlier: the firm trimmed its target from $360 to $330 on August 25 while holding its Outperform rating — a modest vote of reduced conviction that stood out given the general direction of travel. The consensus mean target sits near $411 against a current price of $267, a gap that looks wide on the surface. One Cantor Fitzgerald target of $600 is pulling that average meaningfully higher; strip it out and the central tendency is closer to the $380-$430 cluster. Even using those figures, the stock trades at a 30-40% discount to the Street's base cases. Valuation multiples have compressed over the past month — the P/E has fallen roughly 3.3 points over 30 days to 16.1x, and EV/EBITDA has eased half a turn to 12.6x. EPS momentum factor scores remain among the stronger signals, ranking in the 87th percentile on a 30-day basis and the 71st on 90-day, pointing to sustained upward estimate revisions even as the price retreats.

On insider activity, the picture is uniformly one-way. Net selling over the past 90 days totals approximately 17,500 shares worth $5.5 million. CEO John Lee sold 10,000 shares at $302 on August 14 under a pre-arranged 10b5-1 plan — a programmatic sale that limits its signalling value. The COO's June cluster of sales, however, included transactions outside a 10b5-1 plan, which carries somewhat more weight as a discretionary signal. No insider has bought a share in the period covered. Taken in isolation, that is unremarkable for a large-cap semiconductor name where most insider activity flows through structured plans. But combined with the short position rebuild, it adds texture to the thesis that insiders are not using this pullback as a buying opportunity.

Against its closest peers, MKSI is lagging. COHU gained 24% on the week, UCTT added 11%, and ICHR rose 8.6%. Even the larger-cap names — LRCX and AMAT — posted 1.9% and 4.7% weekly gains respectively. MKSI's 2.7% weekly move keeps it positive but firmly at the bottom of the group. The stock is down 9.2% over the past month while several peers have been rallying. That relative underperformance, combined with the short rebuild and a stock sitting nearly 30% below the bulk of analyst targets, makes the November 4 earnings date the most logical focal point — the question of whether Q2's earnings-day drop of roughly 9% was a reset or the beginning of something more extended will come back into sharp relief.